The Food and Drug Administration has given the green light to a new medication called Merck’s Lipfendra, designed to tackle persistently high cholesterol levels. This new pill offers a daily alternative to the regular injections that patients with severe cholesterol issues often rely on.
High cholesterol is a significant risk factor for cardiovascular diseases and heart attacks. Patients dealing with this problem now have a more convenient treatment option thanks to this recent approval.
Lipfendra’s approval marks a step forward in providing accessible care for those at high risk, potentially improving adherence to treatment and healthcare outcomes for many individuals.
FDA Permits Zyn Nicotine Pouches as Lower Risk Alternative to Cigarettes 
Salad and Go Closes Locations Amid Cyclospora Outbreak Concerns 
Foodborne Pathogens Pose Growing Threats in the U.S. 
Transforming Healthcare with AI: A Human-Centric Approach 
Polyethylene Exposure Linked to Fatty Liver Disease 
Senate Set to Confirm New CDC Director